The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in males - PubMed (original) (raw)

doi: 10.1136/jnnp.2005.063966.

Y Davidson, L Gibbons, A Payton, A M T Richardson, A Varma, C Julien, C Stopford, J Thompson, M A Horan, N Pendleton, S M Pickering-Brown, D Neary, J S Snowden, D M A Mann

Affiliations

The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in males

R Srinivasan et al. J Neurol Neurosurg Psychiatry. 2006 Feb.

Abstract

Objective: To determine whether polymorphic variations in the apolipoprotein E gene (APOE) are associated with increased risk of frontotemporal lobar degeneration (FTLD) when mutation in tau gene is absent.

Methods: The APOE gene was genotyped by polymerase chain reaction from DNA routinely extracted from blood or brain tissues. The APOE epsilon4 allele frequency in 198 patients with FTLD not associated with mutations in tau gene was compared with that of a control group of 756 normal individuals drawn from the same geographical region. Analyses were done according to clinical subtype or sex.

Results: The APOE epsilon4 allele frequency (19.4%) was increased (p = 0.01) in FTLD v the whole control group (14.1%), while the APOE epsilon2 allele frequency in FTLD (6.5%) was slightly lower than in controls (8.0%) (NS). The APOE epsilon4 allele frequency in men with FTLD (22.3%) was greater (p = 0.002) than in male controls (12.3%); the frequency in women (16.3%) was similar to that in female controls (14.8%) (NS). The APOE epsilon2 allele frequency in men with FTLD was 4.9% while in male controls it was 9.5% (p = 0.06), but there was no difference in women (7.5% v 7.9%, NS). Neither the APOE epsilon2 nor APOE epsilon4 allele frequency varied significantly between any of the clinical subtypes.

Conclusions: In FTLD not associated with mutations in tau gene, possession of APOE epsilon4 allele in men roughly doubles the chances of developing disease, whereas this has no impact upon disease risk in women.

PubMed Disclaimer

Conflict of interest statement

Competing interests: none declared

References

    1. Corder E H, Saunders A M, Strittmatter W J.et al Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993261921–923. - PubMed
    1. Czech C, Forstl H, Monning U. ApoE4 in clinically diagnosed Alzheimer's disease, frontal lobe degeneration and non‐demented controls. Neurobiol Ageing 199415(suppl 1)S132
    1. Frisoni G B, Calabresi L, Geroldi C.et al Apolipoprotein E ε4 allele in Alzheimer's disease and vascular dementia. Dementia 19945240–242. - PubMed
    1. Farrer L A, Abraham C R, Volicer L.et al Allele ε4 of apolipoprotein E shows a dose effect on age at onset of Pick disease. Exp Neurol 1995136162–170. - PubMed
    1. Schneider J A, Gearing M, Robbins R S.et al Apolipoprotein E genotype in diverse neurodegenerative disorders. Ann Neurol 199538131–135. - PubMed

MeSH terms

Substances

LinkOut - more resources